FIELD: medicine.
SUBSTANCE: method involves one-time daily oral administration of L-cysteine, at that, the course of treatment is not less than 3 months, and the received single dose is 500 mg.
EFFECT: use of the invention improves the efficiency of treatment of spinocerebellar ataxia type 1 due to neurodegeneration process regression.
3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | 2018 |
|
RU2763425C2 |
| THERAPEUTIC AGENTS AGAINST NEURODEGENERATIVE DISEASES | 2017 |
|
RU2756519C2 |
| DEVICE FOR EQUILIBRIUM RESTORATION WITH CEREBELLAR ATAXIA | 2005 |
|
RU2328261C2 |
| PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS AGAINST LYSOSOMAL STORAGE DISEASES | 2017 |
|
RU2749515C2 |
| METHOD OF DIFFERENTIAL DIAGNOSIS OF SYSTEMIC AND NON-SYSTEMIC DIZZINESS | 2022 |
|
RU2799621C1 |
| METHOD FOR TREATING DISSEMINATED SCLEROSIS | 1991 |
|
RU2016568C1 |
| METHOD OF ESTIMATING WALKING PARAMETERS IN PATIENTS WITH SYNDROME OF CEREBELLAR ATAXIA | 2009 |
|
RU2423914C1 |
| DEUTERATED ANALOGUES OF ACETYLEUCINE | 2019 |
|
RU2810793C2 |
| METHOD FOR TREATING THE CASES OF MULTIPLE SCLEROSIS | 0 |
|
SU1680192A1 |
| THERAPY FOR CLINICAL PRESENTATIONS OF MULTIPLE SCLEROSIS | 2007 |
|
RU2353367C2 |
